Hana Mohsen Ali
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hana Mohsen Ali has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Naif Taleb Ali
Department of Health Sciences, Faculty of Medicine and Health Sciences, University of Science and Technology, Aden, Yemen
5 shared publications - Gamila Saleh Ali
Department of Medicine, Faculty of Medicine and Health Sciences, University of Aden, Aden, Yemen
4 shared publications - Mansour Abdulnabi H. Mehdi
Department of Medical Laboratory, University of Lahej Radfan University College, Al Habilayn, Yemen
4 shared publications - Nazeh Mohammed Al-Abd
Department of Health Sciences, Faculty of Medicine and Health Sciences, University of Science and Technology, Aden, Yemen
2 shared publications Radfan Saleh Abdullah
Department of Medical Laboratory, University of Lahej Radfan University College, Al Habilayn, Yemen
2 shared publications- Radfan Saleh Abdullah
Affiliations Department of Health Sciences, Faculty of Medicine and Health Sciences, University of Science and Technology, Aden, Yemen, Department of Laboratory Sciences, Radfan College University, University of Lahej, Al-Houta, Yemen, Department of Laboratory Sciences, Aden Gulf International University, Al-Dhale, Yemen
2 shared publications
Latest Publications
- Open Access
- 20 July 2026
- Published by Springer Nature in BMC Medical Informatics and Decision Making
- Vol. 26 (1)
AI-assisted decision support for sickle cell disease severity stratification using routine blood tests: a systematic review and meta-analysis
- 20 July 2026
- Published by Springer Nature in BMC Medical Informatics and Decision Making
- Vol. 26 (1)
Open AccessAI-assisted decision support for sickle cell disease severity stratification using routine blood tests: a systematic review and meta-analysis
- Open Access
Systemic inflammation and malaria co-infection in irritable bowel syndrome: a cross-sectional study of 142 Yemeni patients
Objective To determine the prevalence of malaria co-infection among patients with irritable bowel syndrome (IBS) in Yemen and to evaluate the association of systemic inflammatory biomarkers (neutrophil-to-lymphocyte ratio (NLR), mean platelet volume (MPV) and platelet-to-lymphocyte ratio (PLR)) with this co-infection. Design Multicentre, cross-sectional observational study conducted between April and December 2024. Setting Primary and secondary healthcare facilities across 21 governorates in Yemen. Participants 142 consecutive adult patients (aged 18–70 years) diagnosed with IBS according to the Rome IV criteria. Outcome measures The primary outcome was the prevalence of malaria infection, confirmed by a rapid diagnostic test . Secondary outcomes included differences in NLR, MPV and PLR between groups, assessed using independent t-tests, and the diagnostic performance of these biomarkers evaluated by receiver operating characteristic curve analysis with AUC calculation. Multivariate binary logistic regression was used to identify independent predictors of malaria co-infection, adjusting for potential confounders. Results The mean age was 42.3 years (SD 11.7) with an equal gender distribution. The prevalence of malaria co-infection was 45.1% (64/142). Patients with malaria positivity had significantly higher NLR (mean difference 0.56, 95% CI 0.40 to 0.72; pConclusions Nearly half of the Yemeni patients with IBS in this study had malaria co-infection, with the highest burden in diarrhoea-predominant and mixed subtypes. Elevated NLR and PLR were strongly associated with co-infection, suggesting these readily available biomarkers could aid targeted screening in resource-limited, endemic settings.
Open AccessSystemic inflammation and malaria co-infection in irritable bowel syndrome: a cross-sectional study of 142 Yemeni patients
Objective To determine the prevalence of malaria co-infection among patients with irritable bowel syndrome (IBS) in Yemen and to evaluate the association of systemic inflammatory biomarkers (neutrophil-to-lymphocyte ratio (NLR), mean platelet volume (MPV) and platelet-to-lymphocyte ratio (PLR)) with this co-infection. Design Multicentre, cross-sectional observational study conducted between April and December 2024. Setting Primary and secondary healthcare facilities across 21 governorates in Yemen. Participants 142 consecutive adult patients (aged 18–70 years) diagnosed with IBS according to the Rome IV criteria. Outcome measures The primary outcome was the prevalence of malaria infection, confirmed by a rapid diagnostic test . Secondary outcomes included differences in NLR, MPV and PLR between groups, assessed using independent t-tests, and the diagnostic performance of these biomarkers evaluated by receiver operating characteristic curve analysis with AUC calculation. Multivariate binary logistic regression was used to identify independent predictors of malaria co-infection, adjusting for potential confounders. Results The mean age was 42.3 years (SD 11.7) with an equal gender distribution. The prevalence of malaria co-infection was 45.1% (64/142). Patients with malaria positivity had significantly higher NLR (mean difference 0.56, 95% CI 0.40 to 0.72; pConclusions Nearly half of the Yemeni patients with IBS in this study had malaria co-infection, with the highest burden in diarrhoea-predominant and mixed subtypes. Elevated NLR and PLR were strongly associated with co-infection, suggesting these readily available biomarkers could aid targeted screening in resource-limited, endemic settings.
- Open Access
- 29 January 2026
- Published by Springer Nature in Conflict and Health
- Vol. 20 (1)
Mean platelet volume as a Low-Cost discriminatory marker for thrombotic risk assessment in Yemeni type 2 diabetic patients: A proposal for Resource-Limited settings
Thrombotic complications are a leading cause of mortality in type 2 diabetes mellitus (T2DM). In resource-limited settings, identifying affordable and acce
- 29 January 2026
- Published by Springer Nature in Conflict and Health
- Vol. 20 (1)
Open AccessMean platelet volume as a Low-Cost discriminatory marker for thrombotic risk assessment in Yemeni type 2 diabetic patients: A proposal for Resource-Limited settings
Thrombotic complications are a leading cause of mortality in type 2 diabetes mellitus (T2DM). In resource-limited settings, identifying affordable and acce
- Open Access
- 1 January 2026
- Published by Wiley in Human Mutation
- Vol. 2026 (1) , 9405486
AI‐Augmented Hematological Signatures for Equitable Detection of Hereditary Hemolytic Anemia Carriers: A Global Systematic Review and Meta‐Analysis
Artificial intelligence (AI) augmentation of routine hematological tests offers a promising strategy to improve hereditary hemolytic anemia (HHA) carrier detection in premarital screening, especially in resource‐limited settings. HHA in this review specifically encompasses β ‐thalassemia, α ‐thalassemia, sickle cell disease (including HbS and HbC variants), and other hemoglobinopathies with autosomal recessive inheritance patterns requiring carrier detection for prevention. These conditions share hemolytic phenotypes but differ in hematological signatures, necessitating separate subgroup analyses. This global systematic review and meta‐analysis evaluated the diagnostic accuracy, equity implications, and implementation challenges of AI‐augmented complete blood count (CBC), blood smear, and erythrocyte sedimentation rate (ESR) for HHA carrier identification. We systematically searched seven databases and included 85 studies ( n = 133,498 participants, 23 countries). AI‐augmented screening achieved a pooled sensitivity of 92.8% (95% CI: 91.3%–94.1%) and specificity of 91.5% (89.7%–93.0%), representing a 12.3% sensitivity improvement over conventional interpretation ( p < 0.001). However, significant geographic disparities were observed: sensitivity in Sub‐Saharan Africa was 86.5% compared with 94.8% in the Middle East ( p < 0.001), partly due to algorithmic bias against African HbS/HbC variants and infrastructural barriers. Deep learning models achieved the highest sensitivity (95.1%), whereas explainable artificial intelligence (XAI) provided optimal specificity (94.3%). Integrating CBC with blood smear increased specificity by 5.5% at minimal additional cost. AI triage reduced confirmatory testing by 23.7%, saving $8.50 per individual. For equitable implementation, we recommend the following: (1) federated learning to include underrepresented genotypes, (2) WHO/CDC certification of affordable, offline‐capable edge AI devices, and (3) mandatory XAI compliance with bias audits. AI can transform HHA screening, but deliberate efforts are needed to avoid exacerbating global health inequities. Importantly, 68% of validation studies used research‐grade rather than routine clinical samples, and prospective clinic‐to‐algorithm validation remains a critical gap requiring urgent attention before real‐world deployment.
- 1 January 2026
- Published by Wiley in Human Mutation
- Vol. 2026 (1) , 9405486
Open AccessAI‐Augmented Hematological Signatures for Equitable Detection of Hereditary Hemolytic Anemia Carriers: A Global Systematic Review and Meta‐Analysis
Artificial intelligence (AI) augmentation of routine hematological tests offers a promising strategy to improve hereditary hemolytic anemia (HHA) carrier detection in premarital screening, especially in resource‐limited settings. HHA in this review specifically encompasses β ‐thalassemia, α ‐thalassemia, sickle cell disease (including HbS and HbC variants), and other hemoglobinopathies with autosomal recessive inheritance patterns requiring carrier detection for prevention. These conditions share hemolytic phenotypes but differ in hematological signatures, necessitating separate subgroup analyses. This global systematic review and meta‐analysis evaluated the diagnostic accuracy, equity implications, and implementation challenges of AI‐augmented complete blood count (CBC), blood smear, and erythrocyte sedimentation rate (ESR) for HHA carrier identification. We systematically searched seven databases and included 85 studies ( n = 133,498 participants, 23 countries). AI‐augmented screening achieved a pooled sensitivity of 92.8% (95% CI: 91.3%–94.1%) and specificity of 91.5% (89.7%–93.0%), representing a 12.3% sensitivity improvement over conventional interpretation ( p < 0.001). However, significant geographic disparities were observed: sensitivity in Sub‐Saharan Africa was 86.5% compared with 94.8% in the Middle East ( p < 0.001), partly due to algorithmic bias against African HbS/HbC variants and infrastructural barriers. Deep learning models achieved the highest sensitivity (95.1%), whereas explainable artificial intelligence (XAI) provided optimal specificity (94.3%). Integrating CBC with blood smear increased specificity by 5.5% at minimal additional cost. AI triage reduced confirmatory testing by 23.7%, saving $8.50 per individual. For equitable implementation, we recommend the following: (1) federated learning to include underrepresented genotypes, (2) WHO/CDC certification of affordable, offline‐capable edge AI devices, and (3) mandatory XAI compliance with bias audits. AI can transform HHA screening, but deliberate efforts are needed to avoid exacerbating global health inequities. Importantly, 68% of validation studies used research‐grade rather than routine clinical samples, and prospective clinic‐to‐algorithm validation remains a critical gap requiring urgent attention before real‐world deployment.
- Open Access
- 1 July 2025
- Published by BMJ in Lupus Science & Medicine
- Vol. 12 (2) , e001696
NLR outperforms PLR in SLE diagnosis and prognosis: an AI-enhanced meta-analysis of 12 850 patients with ethnicity-specific cut-offs
Objectives: To evaluate the diagnostic and prognostic performance of the neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) in SLE and to integrate these biomarkers into an interpretable artificial intelligence (AI) model for clinical decision support. Design: We conducted a two-phase mixed-methods study: (1) a meta-analysis of 50 studies (n=12 850 patients with SLE), compliant with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses, and (2) the development and validation of an XGBoost machine learning model, guided by the Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis-AI, with SHapley Additive exPlanations (SHAP) explainability. Setting: Our analysis used multicentre data from global SLE registries, including cohorts from Asia, Europe, North America and Africa. Participants: The study included adults (≥18 years) who met the 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for SLE, with NLR and PLR measured via standardised complete blood count. Comparator groups consisted of healthy controls and patients with non-SLE autoimmune diseases. Interventions: NLR and PLR were assessed as biomarkers for SLE activity and complications. Our AI model integrated these ratios with standard clinical biomarkers and multi-omics data. Primary and secondary outcome measures: The primary outcome was diagnostic accuracy (measured by area under the curve (AUC), sensitivity and specificity) for active SLE (defined as Systemic Lupus Erythematosus Disease Activity Index ≥6). Secondary outcomes included prognostic value (HRs for lupus nephritis, cardiovascular events and mortality) and treatment response monitoring. Results: Our analysis demonstrated that NLR has superior diagnostic accuracy for active SLE compared with PLR, with a pooled AUC of 0.85 vs 0.78 (p=0.02). NLR showed pooled sensitivity and specificity of 78% and 82%, respectively, while PLR showed 70% and 75%. Elevated NLR (>3.5) and PLR (>185) predicted higher risks of lupus nephritis (HR=2.1 and 1.8, respectively), cardiovascular events (HR=2.3 and 1.9) and mortality (HR=3.1 and 2.1; all p3.1 for Asian populations, >2.8 for Caucasian populations and >3.4 for African populations. The AI model achieved an AUC of 0.87 in training and 0.82 in validation, with NLR emerging as the top predictive feature (SHAP score=0.25). Conclusion: NLR outperforms PLR in SLE diagnosis and risk stratification, with validated cut-offs that vary significantly by ethnicity. The integration of these biomarkers into AI models enhances predictive accuracy, supporting the use of NLR and PLR as cost-effective tools for SLE management.
- 1 July 2025
- Published by BMJ in Lupus Science & Medicine
- Vol. 12 (2) , e001696
Open AccessNLR outperforms PLR in SLE diagnosis and prognosis: an AI-enhanced meta-analysis of 12 850 patients with ethnicity-specific cut-offs
Objectives: To evaluate the diagnostic and prognostic performance of the neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) in SLE and to integrate these biomarkers into an interpretable artificial intelligence (AI) model for clinical decision support. Design: We conducted a two-phase mixed-methods study: (1) a meta-analysis of 50 studies (n=12 850 patients with SLE), compliant with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses, and (2) the development and validation of an XGBoost machine learning model, guided by the Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis-AI, with SHapley Additive exPlanations (SHAP) explainability. Setting: Our analysis used multicentre data from global SLE registries, including cohorts from Asia, Europe, North America and Africa. Participants: The study included adults (≥18 years) who met the 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for SLE, with NLR and PLR measured via standardised complete blood count. Comparator groups consisted of healthy controls and patients with non-SLE autoimmune diseases. Interventions: NLR and PLR were assessed as biomarkers for SLE activity and complications. Our AI model integrated these ratios with standard clinical biomarkers and multi-omics data. Primary and secondary outcome measures: The primary outcome was diagnostic accuracy (measured by area under the curve (AUC), sensitivity and specificity) for active SLE (defined as Systemic Lupus Erythematosus Disease Activity Index ≥6). Secondary outcomes included prognostic value (HRs for lupus nephritis, cardiovascular events and mortality) and treatment response monitoring. Results: Our analysis demonstrated that NLR has superior diagnostic accuracy for active SLE compared with PLR, with a pooled AUC of 0.85 vs 0.78 (p=0.02). NLR showed pooled sensitivity and specificity of 78% and 82%, respectively, while PLR showed 70% and 75%. Elevated NLR (>3.5) and PLR (>185) predicted higher risks of lupus nephritis (HR=2.1 and 1.8, respectively), cardiovascular events (HR=2.3 and 1.9) and mortality (HR=3.1 and 2.1; all p3.1 for Asian populations, >2.8 for Caucasian populations and >3.4 for African populations. The AI model achieved an AUC of 0.87 in training and 0.82 in validation, with NLR emerging as the top predictive feature (SHAP score=0.25). Conclusion: NLR outperforms PLR in SLE diagnosis and risk stratification, with validated cut-offs that vary significantly by ethnicity. The integration of these biomarkers into AI models enhances predictive accuracy, supporting the use of NLR and PLR as cost-effective tools for SLE management.